DEC 11, 2019 2:20 PM PST

Drug To Treat Ulcerative Colitis

WRITTEN BY: Nouran Amin

Biomedical researchers at the University of California—Riverside, found that the therapeutic drug ‘tofacitinib’ used in treating autoimmunity symptoms of rheumatoid arthritis can also treat gut permeability defects in patients diagnosed with ulcerative colitis. "Our work increases our understanding of how this drug is useful for treating ulcerative colitis," said Declan McCole, a professor of biomedical sciences in the UCR School of Medicine, and the lead author of the study that appears in the journal Inflammatory Bowel Diseases. "We now better understand where in the gut the drug is working, and how."

Ulcerative colitis is a chronic inflammatory bowel disease affecting 1 million Americans. The condition targets the large intestine in the digestive system that results in the lining of the colon becoming inflamed and leaky. But, tofacitinib—often marketed as Xeljianz—can repair the cells lining the gut.

"We found tofacitinib fixes the leakiness in the intestinal barrier," McCole said. "Specifically, it fixes intestinal epithelial permeability defects caused by 'interferon-gamma,' an inflammatory cytokine involved in autoimmune diseases such as ulcerative colitis and rheumatoid arthritis."

Learn more about ulcerative colitis:

Intestinal permeability, or leakiness, is a characteristic of ulcerative colitis and results in inflammation. Researchers believe that tofacitinib targets the inflammation-induced permeability in the lining and prevents fluid loss.

"By targeting specific molecules, the drug inhibits a pathway that is activated by inflammation," said Anica Sayoc-Becerra, a graduate student in the Biomedical Sciences Graduate Program, a member of McCole's lab, and the first author of the research paper. "Our study shows tofacitinib is not just acting on immune cells, as was first thought, but can have a direct effect on the epithelial cells that are the key factor in maintaining gut barrier function."

Source: University of California

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
JUN 18, 2020
Drug Discovery & Development
Gilead to Trial COVID-19 Drug on Children
JUN 18, 2020
Gilead to Trial COVID-19 Drug on Children
Following the emergency use authorization given to Remdesivir on May 1, Gilead Sciences has announced that it will condu ...
JUL 02, 2020
Drug Discovery & Development
Common Asthma Drug Could Treat Alzheimer's
JUL 02, 2020
Common Asthma Drug Could Treat Alzheimer's
Researchers from Lancaster University, England, have found that Salbutamol, a medication commonly used to treat asthma, ...
JUL 16, 2020
Cardiology
A New Drug Candidate to Combat Cardiac Fibrosis
JUL 16, 2020
A New Drug Candidate to Combat Cardiac Fibrosis
Medicine is undoubtedly reaching a golden age, as researchers expand diagnostic and therapeutic tools like never before. ...
JUL 17, 2020
Drug Discovery & Development
Could Low-Dose Radiation Therapy Treat COVID-19?
JUL 17, 2020
Could Low-Dose Radiation Therapy Treat COVID-19?
Research from a century ago points towards the potential of low-dose radiation therapy (LDRT) for treating pneumonia. Ev ...
JUL 21, 2020
Cardiology
Investigating New Anti-Blood Clotting Treatments
JUL 21, 2020
Investigating New Anti-Blood Clotting Treatments
When it comes to your cardiovascular health, it is important to look at more than just your heart. The cardiovascular sy ...
JUL 20, 2020
Technology
Robots as Models for Medicated Chewing Gum
JUL 20, 2020
Robots as Models for Medicated Chewing Gum
A robot with the ability to chew can provide useful insights on medicated chewing gum for pharmaceutical companies. The ...
Loading Comments...